{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:05Z","timestamp":1794047465983,"version":"4.8.0"},"reference-count":45,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Belantamab mafodotin (belantamab) is a first-in-class anti-B-cell maturation antigen (BCMA) antibody-drug conjugate approved for the treatment of triple-class refractory multiple myeloma. It provides a unique therapeutic option for patients ineligible for chimeric antigen receptor (CAR) T and bispecific antibody therapy, and\/or patients progressing on anti-CD38 treatment where CAR T and bispecifics might be kept in reserve. Wider use of the drug can be challenged by its distinct ocular side effect profile, including corneal microcysts and keratopathy. While dose reduction has been the most effective way to reduce these toxicities, the underlying mechanism of this BCMA off-target effect remains to be characterized. In this study, we provide the first evidence for soluble BCMA (sBCMA) in lacrimal fluid and report on its correlation with tumor burden in myeloma patients. We confirm that corneal cells do not express BCMA, and show that sBCMA-belantamab complexes may rather be internalized by corneal epithelial cells through receptor-ligand independent pinocytosis. Using an hTcEpi corneal cell-line model, we show that the pinocytosis inhibitor EIPA significantly reduces belantamab-specific cell killing. As a proof of concept, we provide detailed patient profiles demonstrating that, after belantamab-induced cell killing, sBCMA is released into circulation, followed by a delayed increase of sBCMA in the tear fluid and subsequent onset of keratopathy. Based on the proposed mechanism, pinocytosis-induced keratopathy can be prevented by lowering the entry of sBCMA into the lacrimal fluid. Future therapeutic concepts may therefore consist of belantamab-free debulking therapy prior to belantamab consolidation and\/or concomitant use of \u03b3-secretase inhibition as currently evaluated for belantamab and nirogacestat in ongoing studies.<\/jats:p>","DOI":"10.3324\/haematol.2024.285205","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T03:57:17Z","timestamp":1712203037000},"page":"3670-3680","source":"Crossref","is-referenced-by-count":4,"title":["Soluble B-cell maturation antigen in lacrimal fluid as a potential biomarker and mediator of keratopathy in multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Umair","family":"Munawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Theuersbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Steinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungbin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nerreter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Katrin","family":"Regensburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Teufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Bittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malik S.","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jost","family":"Hillenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Kampik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes M.","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"68609","doi-asserted-by":"crossref","unstructured":"La\u00e2bi Y, Gras MP, Carbonnel F. A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16) (q26;p13) translocation in a malignant T cell lymphoma. EMBO J. 1992; 11(11):3897-3904.","DOI":"10.1002\/j.1460-2075.1992.tb05482.x"},{"key":"68610","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD, Shah N. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021; 384(8):705-716.","DOI":"10.1056\/NEJMoa2024850"},{"key":"68611","doi-asserted-by":"crossref","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023; 388(11):1002-1014.","DOI":"10.1056\/NEJMoa2213614"},{"key":"68612","doi-asserted-by":"crossref","unstructured":"Berdeja JG, Madduri D, Usmani SZ. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet. 2021; 398(10297):314-324.","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"68613","doi-asserted-by":"crossref","unstructured":"Martin T, Usmani SZ, Berdeja JG. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023; 41(6):1265-1274.","DOI":"10.1200\/JCO.22.00842"},{"key":"68614","doi-asserted-by":"crossref","unstructured":"Usmani SZ, Garfall AL, van de Donk NWCJ. Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021; 398(10301):665-674.","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"68615","doi-asserted-by":"crossref","unstructured":"Rejeski K, Perez A, Sesques P. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/ refractory large B-cell lymphoma. Blood. 2021; 138(24):2499-2513.","DOI":"10.1182\/blood.2020010543"},{"key":"68616","doi-asserted-by":"crossref","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021; 27(12):2099-2103.","DOI":"10.1038\/s41591-021-01564-7"},{"key":"68617","doi-asserted-by":"crossref","unstructured":"Lin Y, Martin TG, Usmani SZ. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2023; 41(16_suppl):8009.","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"key":"68618","doi-asserted-by":"crossref","unstructured":"Dhodapkar KM, Cohen AD, Kaushal A. Changes in bone marrow tumor and immune cells correlate with durability of remissions following BCMA CAR T therapy in myeloma. Blood Cancer Discov. 2022; 3(6):490-501.","DOI":"10.1158\/2643-3230.BCD-22-0018"},{"key":"68619","doi-asserted-by":"crossref","unstructured":"Garfall AL, Dancy EK, Cohen AD. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Adv. 2019; 3(19):2812-2815.","DOI":"10.1182\/bloodadvances.2019000600"},{"key":"68620","doi-asserted-by":"crossref","unstructured":"Firestone RS, McAvoy D, Shekarkhand T. CD8 effector T cells enhance response in BCMA-exposed and -na\u00efve multiple myeloma. Blood Adv. 2024; 8(7):1600-1611.","DOI":"10.1182\/bloodadvances.2023011225"},{"key":"68621","doi-asserted-by":"crossref","unstructured":"Tai Y-T, Mayes PA, Acharya C. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014; 123(20):3128-3138.","DOI":"10.1182\/blood-2013-10-535088"},{"key":"68622","doi-asserted-by":"crossref","unstructured":"Trudel S, Lendvai N, Popat R. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018; 19(12):1641-1653.","DOI":"10.1016\/S1470-2045(18)30576-X"},{"key":"68623","doi-asserted-by":"crossref","unstructured":"Trudel S, Lendvai N, Popat R. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019; 9(4):37.","DOI":"10.1038\/s41408-019-0196-6"},{"key":"68624","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020; 21(2):207-221.","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"68625","doi-asserted-by":"crossref","unstructured":"Richardson PG, Lee HC, Abdallah A-O. Single-agent belantamab mafodotin for relapsed\/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study. Blood Cancer J. 2020; 10(10):106.","DOI":"10.1038\/s41408-020-00369-0"},{"key":"68626","doi-asserted-by":"crossref","unstructured":"Dimopoulos MA, Hungria VTM, Radinoff A. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023; 10(10):e801-e812.","DOI":"10.1016\/S2352-3026(23)00243-0"},{"key":"68627","doi-asserted-by":"crossref","unstructured":"Nooka AK, Weisel K, van de Donk NW. Belantamab mafodotin in combination with novel agents in relapsed\/ refractory multiple myeloma: DREAMM-5 study design. Future Oncol. 2021; 17(16):1987-2003.","DOI":"10.2217\/fon-2020-1269"},{"key":"68628","doi-asserted-by":"crossref","unstructured":"Trudel S, McCurdy A, Louzada ML. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial. Nat Med. 2024; 30(2):543-551.","DOI":"10.1038\/s41591-023-02703-y"},{"key":"68629","doi-asserted-by":"crossref","unstructured":"Trudel S, Davis R, Lewis NM. DREAMM-8: a phase III study of the efficacy and safety of belantamab mafodotin with pomalidomide and dexamethasone (B-Pd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2020; 136(Suppl 1):4.","DOI":"10.1182\/blood-2020-139785"},{"key":"68630","unstructured":"Press release: GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in relapsed\/refractory multiple myeloma. 2024. Publisher Full Text|"},{"key":"68631","doi-asserted-by":"crossref","unstructured":"Nooka AK, Cohen AD, Lee HC. Single-agent belantamab mafodotin in patients with relapsed\/refractory multiple myeloma: final analysis of the DREAMM-2 trial. Cancer. 2023; 129(23):3746-3760.","DOI":"10.1002\/cncr.34987"},{"key":"68632","doi-asserted-by":"crossref","unstructured":"Marquant K, Quinquenel A, Arndt C, Denoyer A. Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report. J Hematol Oncol. 2021; 14(1):159.","DOI":"10.1186\/s13045-021-01172-5"},{"key":"68633","doi-asserted-by":"crossref","unstructured":"Lonial S, Nooka AK, Thulasi P. Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM). Blood Cancer J. 2021; 11(5):103.","DOI":"10.1038\/s41408-021-00494-4"},{"key":"68634","doi-asserted-by":"crossref","unstructured":"Laurent SA, Hoffmann FS, Kuhn P-H. \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015; 6:7333.","DOI":"10.1038\/ncomms8333"},{"key":"68635","doi-asserted-by":"crossref","unstructured":"Wahab A, Rafae A, Mushtaq K. Ocular toxicity of belantamab mafodotin, an oncological perspective of management in relapsed and refractory multiple myeloma. Front Oncol. 2021; 11:678634.","DOI":"10.3389\/fonc.2021.678634"},{"key":"68636","unstructured":"The Human Protein Atlas. 2024. Publisher Full Text|"},{"key":"68637","doi-asserted-by":"crossref","unstructured":"Karlsson M, Zhang C, M\u00e9ar L. A single-cell type transcriptomics map of human tissues. Sci Adv. 2021; 7(31):eabh2169.","DOI":"10.1126\/sciadv.abh2169"},{"key":"68638","doi-asserted-by":"crossref","unstructured":"Sanchez E, Li M, Kitto A. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012; 158(6):727-738.","DOI":"10.1111\/j.1365-2141.2012.09241.x"},{"key":"68639","doi-asserted-by":"crossref","unstructured":"Visram A, Soof C, Rajkumar SV. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021; 11(6):120.","DOI":"10.1038\/s41408-021-00505-4"},{"key":"68640","doi-asserted-by":"crossref","unstructured":"Peng H, Park JK, Lavker RM. Autophagy and macropinocytosis: keeping an eye on the corneal\/limbal epithelia. Invest Ophthalmol Vis Sci. 2017; 58(1):416-423.","DOI":"10.1167\/iovs.16-21111"},{"key":"68641","doi-asserted-by":"crossref","unstructured":"Alomari M, Kunacheewa C, Manasanch EE. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leuk Lymphoma. 2023; 64(2):261-272.","DOI":"10.1080\/10428194.2022.2133540"},{"key":"68642","doi-asserted-by":"crossref","unstructured":"Shen Y, Liu J, Wang B. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. Curr Res Transl Med. 2023; 71(2):103378.","DOI":"10.1016\/j.retram.2023.103378"},{"key":"68643","doi-asserted-by":"crossref","unstructured":"Farooq AV, Degli Esposti S, Popat R. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol Ther. 2020; 9(4):889-911.","DOI":"10.1007\/s40123-020-00280-8"},{"key":"68644","doi-asserted-by":"crossref","unstructured":"Zhao H, Atkinson J, Gulesserian S. Modulation of macropinocytosis-mediated internalization decreases ocular toxicity of antibody-drug conjugates. Cancer Res. 2018; 78(8):2115-2126.","DOI":"10.1158\/0008-5472.CAN-17-3202"},{"key":"68645","doi-asserted-by":"crossref","unstructured":"Mahalingaiah PK, Ciurlionis R, Durbin KR. Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates. Pharmacol Ther. 2019; 200:110-125.","DOI":"10.1016\/j.pharmthera.2019.04.008"},{"key":"68646","doi-asserted-by":"crossref","unstructured":"Bernitt E, D\u00f6bereiner H-G, Gov NS, Yochelis A. Fronts and waves of actin polymerization in a bistability-based mechanism of circular dorsal ruffles. Nat Commun. 2017; 8:15863.","DOI":"10.1038\/ncomms15863"},{"key":"68647","doi-asserted-by":"crossref","unstructured":"Commisso C, Davidson SM, Soydaner-Azeloglu RG. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013; 497(7451):633-637.","DOI":"10.1038\/nature12138"},{"key":"68648","doi-asserted-by":"crossref","unstructured":"Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful?. Methods Mol Biol. 2008; 440:15-33.","DOI":"10.1007\/978-1-59745-178-9_2"},{"key":"68649","doi-asserted-by":"crossref","unstructured":"Lin H-P, Singla B, Ghoshal P. Identification of novel macropinocytosis inhibitors using a rational screen of Food and Drug Administration-approved drugs. Br J Pharmacol. 2018; 175(18):3640-3655.","DOI":"10.1111\/bph.14429"},{"key":"68650","doi-asserted-by":"crossref","unstructured":"Popat R, Warcel D, O\u2019Nions J. Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial. Haematologica. 2020; 105(5):e261-e263.","DOI":"10.3324\/haematol.2019.235937"},{"key":"68651","doi-asserted-by":"crossref","unstructured":"Keye P, Engelhardt M, W\u00e4sch R, B\u00f6hringer D, Reinhard T. Management of belantamab mafodotin-associated keratopathy with rigid gas-permeable corneal contact lenses. Cornea. 2023; 42(6):744-746.","DOI":"10.1097\/ICO.0000000000003237"},{"key":"68652","doi-asserted-by":"crossref","unstructured":"Pont MJ, Hill T, Cole GO. \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019; 134(19):1585-1597.","DOI":"10.1182\/blood.2019000050"},{"key":"68653","doi-asserted-by":"crossref","unstructured":"Callander N, Richardson P, Hus M. P913: Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs. belamaf monotherapy in patients with relapsed\/refractory multiple myeloma (RRMM): phase 1\/2 DREAMM-5 platform sub-study 3. Hemasphere. 2023; 7(Suppl):e9722122.","DOI":"10.1097\/01.HS9.0000970556.97221.22"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285205\/76853","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285205\/77710","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11546\/76853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:08Z","timestamp":1794045968000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285205","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,4]]}}}